FOLD

NEUTRALM&A

Amicus Therapeutics, Inc.

2026-03-19

Price

$14.38

+0.07%

Score6.5Priority

Signals5/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume1.0xvs 20d avg

Analysis

Amicus Therapeutics (FOLD) is trading as a definitive merger arbitrage play following BioMarin's December 2025 agreement to acquire the company for $14.50 per share in an all-cash deal. The stock's exceptionally low annualized volatility of 1.7% and accumulation signals like QUIET_STORM and STEADY_CLIMB perfectly reflect its pinned price action just pennies below the buyout offer. In the current RISK_OFF geopolitical regime, FOLD is acting as a safe-haven cash proxy for institutions. This high-conviction price discovery is further supported by remarkably tight credit markets (0.91% OAS), which ensure that BioMarin's deal financing remains secure despite broader equity market turbulence.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSPERFECT STACKQUIET ACCUMULATION

Key Takeaways

ActionableThesis:FOLDistradingat$14.38, offeringahighlyinsulated~0.8%arbitragespreadtoBioMarin's$14.50all-cashoffer, actingasasafehavenagainstgeopoliticalvolatility[1.4].
Key Risk: The primary downside tail-risk is an unexpected antitrust block by the FTC/DOJ or a breakdown in deal financing, though tight credit spreads currently mitigate the latter.
What to Watch: Monitor the timeline for the Q2 2026 expected close, specifically watching for final regulatory clearances and shareholder vote confirmations.

← Back to 2026-03-19 View Full FOLD History →Yahoo Finance &nearr;